US 12,319,969 B2
Detecting esophageal disorders
David A. Ahlquist, Rochester, MN (US); William R. Taylor, Lake City, MN (US); John B. Kisiel, Rochester, MN (US); Douglas W. Mahoney, Elgin, MN (US); Tracy C. Yab, Rochester, MN (US); Graham P. Lidgard, Middleton, WI (US); and Hatim T. Allawi, Middleton, WI (US)
Assigned to Exact Sciences Corporation, Madison, WI (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Exact Sciences Corporation, Madison, WI (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Aug. 24, 2021, as Appl. No. 17/410,383.
Application 17/410,383 is a continuation of application No. 16/570,782, filed on Sep. 13, 2019, granted, now 11,104,960.
Application 16/570,782 is a continuation of application No. 15/550,703, granted, now 10,435,755, issued on Oct. 8, 2019, previously published as PCT/US2016/023782, filed on Mar. 23, 2016.
Claims priority of provisional application 62/139,243, filed on Mar. 27, 2015.
Prior Publication US 2021/0381066 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C07H 21/04 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)
CPC C12Q 1/6886 (2013.01) [C12Q 1/6883 (2013.01); G01N 33/57407 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/166 (2013.01); G01N 2440/12 (2013.01); G01N 2800/14 (2013.01)] 14 Claims
 
1. A method comprising:
extracting genomic DNA from a biological sample from a human individual suspected of having or having an esophageal disorder,
treating the extracted genomic DNA with bisulfite,
amplifying the bisulfite-treated genomic DNA using primers specific for each of ten or fewer markers, and
measuring a methylation level of at least one differentially methylated region (DMR) in each of the ten or fewer markers using methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genomic sequencing PCR,
wherein the ten or fewer markers comprise VAV3.